Omega Therapeutics, Inc.
omegatherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 14, 2024. Its latest SEC filing is a 15-12G from Mar 31, 2025.
10-Q for Q3 FY2024, filed Nov 14, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops programmable mRNA medicines that adjust gene activity for cancer, regenerative medicine, and multigenic diseases.
10-K for FY2023, filed Mar 28, 2024Omega Therapeutics is a clinical-stage biotechnology company pioneering a new class of programmable epigenomic mRNA medicines. Our OMEGA…View ↗
Oncology. Control of target oncogenes including historically challenging, auto-regulatory or un-druggable targets in various cancers.View ↗
Multigenic diseases including immunologic and cardiometabolic conditions. Regulation of multiple genes within an IGD or across IGDs.View ↗
Regenerative medicine. Recapitulation of developmental and mature-state gene expression to drive cellular regeneration and restore normal…View ↗
How Did They Make Money?
A partner pays for licensed research and development rights with upfront cash, possible development and sales milestones, and royalties on net sales of a resulting product.
10-K for FY2023, filed Mar 28, 2024On December 31, 2023, we entered into a Research Collaboration Agreement (the “Novo RCA”) with Novo Nordisk A/S (“Novo Nordisk”)…View ↗
$3.1M
-
10-K for FY2023, filed Mar 28, 2024
$3.1M ↗
Who Were Their Customers?
Research partners such as Novo Nordisk work directly with Omega under agreements that license intellectual property for joint drug development.
10-K for FY2023, filed Mar 28, 2024On December 31, 2023, we entered into a Research Collaboration Agreement (the “Novo RCA”) with Novo Nordisk A/S (“Novo Nordisk”)…View ↗
Did Revenues Turn Into Profits?
No. It lost $97.4M in FY2023.
10-K for FY2023, filed Mar 28, 2024
−$100.3MView ↗
10-K for FY2023, filed Mar 28, 2024
−$97.4MView ↗
10-K for FY2023, filed Mar 28, 2024
−$94.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 14, 2024
−$16.4MView ↗
- ▼ −26% (Loss)
- vs −$22.2M in Q3 FY2023
-
Feb 24, 2025
Agreed to sell substantially all assets; Nasdaq decided to delist shares
The proposed credit bid is at least $11,461,086.00 plus certain liabilities, subject to court approval and higher bids.
Sources
8-K, filed Feb 24, 2025
On February 21, 2025, the Debtor and PM08-B formally entered into the Stalking Horse Agreement. Pursuant to the terms of the Stalking Horse…View ↗
-
Feb 14, 2025
Filed for Chapter 11 bankruptcy
Sources
8-K, filed Feb 14, 2025
On February 10, 2025 (the “Petition Date”), Omega Therapeutics, Inc. (the “Company” or “Debtor”) commenced a chapter 11 case (the “Chapter…View ↗
-
Nov 14, 2024
CEO resigned; chief business officer became president and CEO
Sources
8-K, filed Nov 14, 2024
On November 14, 2024 (the “Transition Date”), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a…View ↗
Who Did They Compete With?
Competes with Alnylam Pharmaceuticals, Beam Therapeutics, Biogen, CRISPR Therapeutics, Editas Medicine, Ionis Pharmaceuticals, Intellia Therapeutics, Janssen Pharmaceuticals, Pfizer, Sangamo Therapeutics, AstraZeneca, Ascletis Pharma, Bio-Path Holdings, Nitto Denko, Simaomics, InteRNA Technologies, Momotaro-Gene, Genprex, and MiNA Therapeutics
10-K for FY2023, filed Mar 28, 2024We expect to compete with companies developing technologies that focus on gene-expression control using various technologies, such as…View ↗
Loading...
